← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

Vaddi Krishna

Chief Executive Officer

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001824633

Purchase history

Companies traded
1
Purchases · 12M
0
Purchases · 24M
7
Average purchase
$99.6K
Median purchase
$29.3K
Gross purchase value
$696.9K

Companies: Prelude Therapeutics Inc

7 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2025-03-27Prelude Therapeutics IncPRLDChief Executive Officer$465.7KOpen filing
2025-03-24Prelude Therapeutics IncPRLDChief Executive Officer$14.9KOpen filing
2025-03-18Prelude Therapeutics IncPRLDChief Executive Officer$29.3KOpen filing
2025-03-14Prelude Therapeutics IncPRLDChief Executive Officer$69.7KOpen filing
2025-01-03Prelude Therapeutics IncPRLDChief Executive Officer$6.0KOpen filing
2025-01-02Prelude Therapeutics IncPRLDChief Executive Officer$12.0KOpen filing
2024-12-20Prelude Therapeutics IncPRLDChief Executive Officer$99.1KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

PeriodCompleted eventsPrice coverageHit rateMedian excess returnAverage excess returnWorst excess return
5D7Developing100.0% (7/7)28.6% (2/7)-5.1%-5.2%-24.1%
20D7Developing100.0% (7/7)42.9% (3/7)-0.1%+4.7%-21.8%
60D7Developing100.0% (7/7)57.1% (4/7)+15.5%-0.2%-41.0%
120D7Developing100.0% (7/7)57.1% (4/7)+31.0%+7.2%-46.8%

Research patterns

First purchase in 12M
0/6
Large purchase ≥ $100k
1/7
Cluster buying · 15D
4/7
Buying the dip
7/7

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.